Final Program

TUESDAY • MAY 17 237
management of cardiac sarcoidosis, fibrotic pulmonary sarcoidosis, and
pulmonary hypertension - the phenotypes of sarcoidosis most associated with
poor outcomes and increased mortality. Following this, we review indications
and use of currently available immunosuppressive agents, and introduce
potential new therapies for sarcoidosis by summarizing the status of current
clinical trials.
Chairing: K.C. Patterson, MD, Philadelphia, PA
A.S. Morgenthau, MD, New York, NY
9:00 A Patient’s Perspective
J. Ploudre, St. Louis, MO
9:05 Etiology and Immunopathogenesis of Sarcoidosis
D.R. Moller, MD, Baltimore, MD
9:20 When Is a Sarcoidosis Patient in Danger from Their Disease
and in Need of Treatment?
A.U. Wells, MD, London, United Kingdom
9:35 When Should We Move on from Prednisone and What Should
We Give?
J.C. Grutters, MD, PhD, Nieuwegein, Netherlands
9:50 What Is the Role of Immunosuppression in Preventing
Pulmonary Fibrosis in Sarcoidosis?
K.C. Patterson, MD, Philadelphia, PA
10:05 Should Sarcoidosis-Associated Pulmonary Hypertension be
Treated?
R.P. Baughman, MD, Cincinnati, OH
10:20 How Should We Diagnose and Treat Cardiac Sarcoidosis?
D.A. Culver, DO, Cleveland, OH
10:35 What Are the Potential New Treatments for Sarcoidosis? An
Update on Clinical Trials
A.S. Morgenthau, MD, New York, NY
C4
CLINICAL
CRITICAL CARE TRACK
CME Credits Available: 2.0
SEPSIS CARE FROM START TO FINISH
Assemblies on Critical Care; Clinical Problems; Nursing
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3000/3002/3004 (West Building, Level 3)
Target Audience
Clinicians and researchers who seek to improve the care of sepsis patients.
Objectives
At the conclusion of this session, the participant will be able to:
• understand methods of improving the early identification of sepsis, including
public awareness campaigns, EMS identification, and SOFA score in
ER/hospital ward;
• deliver evidence-based care, including fluid-resuscitation, use of e-ICU;
• improve health system approaches to quality improvement and addressing
long-term sequelae of sepsis.
Sepsis is the single most expensive cause of hospitalization and the largest
contributor to hospital death. Despite its staggering impact, almost nothing is
known about how to treat sepsis patients outside of the six “golden hours”
immediately after presentation. In this session, leading experts will review the
emerging evidence to inform clinicians about improving sepsis treatment across
different time windows and discuss critical knowledge gaps that require future
research. In the process, attendees will gain new insight into the intersection of
sepsis with pre-hospital care, sepsis care on the wards, sepsis related hospital
readmission, and systems-level sepsis quality improvement.
Chairing: V. Liu, MD, MS, Oakland, CA
H.C. Prescott, MD, MA, Ann Arbor, MI
9:00 Sepsis Screening in the Community: How Do We Inform
the Public?
S. Simpson, MD, Kansas City, KS
9:18 Pre-Hospital Care of Sepsis: Leveraging Emergency Medical
Service Providers
C.W. Seymour, MD, MSc, Pittsburgh, PA
9:35 Life After Rivers: Neither EGDT Nor Neglect
S. Peake, PhD, Victoria, Australia
9:52 Identifying Sepsis Outside the ICU: SIRS or qSOFA?
D.C. Angus, MD, MPH, Pittsburgh, PA
10:09 Enabling Best Sepsis Care Through Tele-Medicine
D.W. Ford, MD, MSCR, Charleston, SC
10:26 The Long Tail of Sepsis: Readmissions and Beyond
H.C. Prescott, MD, MA, Ann Arbor, MI
10:43 Optimizing Learning Health Care Systems to Address Sepsis
V. Liu, MD, MS, Oakland, CA
C5
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
THE BRAIN AFTER CRITICAL ILLNESS:
POPULATIONS, PATIENTS, AND PATHWAYS
Assemblies on Critical Care; Behavioral Science and Health Services
Research
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3006/3008 (West Building, Level 3)
Target Audience
Critical care providers; those with research or clinical interest in long term
outcomes after hospitalization or critical illness.
Objectives
At the conclusion of this session, the participant will be able to:
• define the severity and frequency of long-term brain disorders after critical
illness;
• improve quality of life for patients by discussing long term outcomes after
critical illness and informing patients and families about the impact of
treatment decisions;
• understand the role of the critical care community in leveraging existing
studies to improve our understanding of survivorship after critical illness.
TUESDAY MORNING
ATS 2016 • San Francisco